Silicon Investor (SI) -- The First Internet Community

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : wla(warner lambert) -- Ignore unavailable to you. Want to Upgrade?

To: t36 who wrote (166)	12/11/1997 3:26:00 AM
From: Henry Niman	Read Replies (2) \| Respond to of 942

sue, My expertise is really in the molecular area, not finance. I think that the reaction to the Rezulin associated liver problems was somewhat overblown, but it is a concern because of 2nd generation compounds (which are effective at lower doses) in adavnced trials. From a science side, I think that WLA should have done a deal with LGND, and a deal with AGN at this time would not surprise me. However, such a deal would not yield approved products for several years, so the impact on the stock price of a large company like WLA may not be significant initially.